The Risk of Breast Cancer in Relation to Hormone Replacement Therapy

  • Carlo La Vecchia
Part of the Medical Science Symposia Series book series (MSSS, volume 11)


Despite more than three dozen published studies, several controversial questions remain regarding the relationship between hormone replacement treatment (HRT) and breast cancer.


Breast Cancer Breast Cancer Risk Hormone Replacement Therapy Current User Estrogen Replacement Therapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Mann RD, editor. Hormone Replacement Therapy and Breast Cancer Risk. Carnforth: The Parthenon Publishing Group, 1992.Google Scholar
  2. 2.
    La Vecchia C. Breast cancer risk in hormone replacement therapy-treated women. In Women’s Health in Menopause. Behaviour, Cancer, Cardiovascular Disease, Hormone Replacement Therapy. Kluwer, Dordrecht, 1994;67–73.Google Scholar
  3. 3.
    La Vecchia C. Oestrogens and progestins and breast cancer risk in post-menopausal women. Pharmacol Res 1995;32: 323–4.PubMedCrossRefGoogle Scholar
  4. 4.
    Brinton LA, Schairer C. Estrogen replacement therapy and breast cancer risk. Epidemiol Rev 1993;15:66–79.PubMedGoogle Scholar
  5. 5.
    Stanford JL, Weiss NS, Voigt LF, Daling JR, Habel LA, Rossing MA. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 1995;274:137–42.PubMedCrossRefGoogle Scholar
  6. 6.
    Adami H-O, Persson I. Hormone replacement and breast cancer. A remaining controversy? JAMA 1995;274:178–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Willis DB, Calle EE, Miracle-McMahill HL, Heath CW Jr. Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States. Cancer Causes and Control 1996;7:449–57.PubMedCrossRefGoogle Scholar
  8. 8.
    Mack TM, Ross RK. Risks and benefits of long-term treatment with estrogens. Schweiz Med Wschr 1989;119: 1811–20.PubMedGoogle Scholar
  9. 9.
    Wynder EL. Epidemiological issues in weak associations. Int J Epidemiol 1990; 19(Suppl 1):S5–S7.PubMedCrossRefGoogle Scholar
  10. 10.
    Bergkvist L, Adami H-O, Persson I, Hoover R, Schairer C. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 1989;321:293–7.PubMedCrossRefGoogle Scholar
  11. 11.
    La Vecchia C, Decarli A, Di Pietro S, Franceschi S, Negri E, Parazzini F. Menstrual cycle patterns and the risk of breast disease. Eur J Cancer Clin Oncol 1985;21: 417–22.PubMedCrossRefGoogle Scholar
  12. 12.
    Henderson BE, Ross RK, Judd HL, Krailo MD, Pike MC. Do regular ovulatory cycles increase breast cancer risk? Cancer 1985;56:1206–8.PubMedCrossRefGoogle Scholar
  13. 13.
    Pike MC, Spicer DV, Dahmoush L, Press MF. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 1993;15:17–35.PubMedGoogle Scholar
  14. 14.
    Stanford JL, Thomas DH. Exogenous progestins and breast cancer. Epidemiol Rev 1993; 15: 98–107.PubMedGoogle Scholar
  15. 15.
    Hunt K, Vessey M, McPherson K, Coleman M. Long-term surveillance of mortality and cancer incidence in women receiving hormone replacement therapy. Br J Obstet Gynecol 1987;94: 620–35.CrossRefGoogle Scholar
  16. 16.
    Ewertz M. Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. Int J Cancer 1988;42: 832–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, Hennekens C, Rosner B, Speizer FE. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589–93.PubMedCrossRefGoogle Scholar
  18. 18.
    Day NE. Epidemiology: The role of multi-stage models. Cancer Surveys 1983;2: 579–93.Google Scholar
  19. 19.
    Henderson BE. The cancer question: an overview of recent epidemiologic and retrospective data. Am J Obstet Gynecol 1989; 161: 1859–64.PubMedGoogle Scholar
  20. 20.
    Steinberg KK, Thacker SB, Smith SJ, Stroup DF, Zack MM, Flanders WD, Berkelman RL. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991;265:1985–1990.PubMedCrossRefGoogle Scholar
  21. 21.
    La Vecchia C, Negri E, Franceschi S, Favero A, Nanni O, Filiberti R, Conti E, Montella M, Veronesi A, Ferraroni M, Decarli A. Hormone replacement treatment and breast cancer risk: a cooperative Italian study. Br J Cancer 1995;72: 244–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Lobo RA (1995). Benefits and risks and risks of estrogen replacement therapy. Am J Obstetr Gynecol 1995;173:982–90.CrossRefGoogle Scholar
  23. 23.
    Parazzini F, La Vecchia C, Negri E, Bianchi C, Fedele L. Determinants of estrogen replacement therapy use in Northern Italy. Rev Epidemiol Santé Publique 1993;41:53–8.PubMedGoogle Scholar
  24. 24.
    Magrini N, Vaccheri A, Montanaro M. The Italian way of osteoporosis. Lancet 1992;339:499–500.PubMedCrossRefGoogle Scholar
  25. 25.
    Tavani A, Braga C, La Vecchia C, Negri E, Franceschi S. Hormone replacement treatment and breast cancer risk: An age-specific analysis. Cancer Epidemiol Biomarkers Prev 1997; in press.Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1997

Authors and Affiliations

  • Carlo La Vecchia

There are no affiliations available

Personalised recommendations